DermaSensor

Company profile

About DermaSensor

DermaSensor is a medical technology company that develops AI-driven solutions for early skin cancer detection at the point of care. The company's flagship product is an FDA-cleared, handheld device that combines advanced optical spectroscopy with artificial intelligence to analyze suspicious skin lesions in real-time. The device delivers results in approximately 30 seconds, helping healthcare professionals assess the malignancy risk of skin lesions with 96% sensitivity across the three most common types of skin cancer: melanoma, squamous cell carcinoma, and basal cell carcinoma. The DermaSensor device uses Elastic Scattering Spectroscopy (ESS) technology, which has been validated in over 30 publications across various tissue types. The device's tip reflects and records quick bursts of light off the lesion's cellular and sub-cellular content, which is then analyzed by a built-in computer using proprietary algorithms developed and refined over a decade of clinical research. These algorithms have been trained on thousands of diagnosed lesions to provide an immediate 'Investigate Further' or 'Monitor' output based on the lesion's malignancy risk level. DermaSensor serves a wide range of healthcare specialties including family medicine, internal medicine, concierge practices, health systems, and walk-in clinics. The company's mission is to empower healthcare professionals with data-driven, breakthrough solutions that improve early skin cancer detection and save lives. The technology is particularly valuable in addressing the challenge of long wait times for dermatology referrals, which can range from 4-6 months in many areas, and helps non-dermatology physicians enhance their clinical confidence in skin cancer assessment. The device has been integrated into medical training programs and is supported by 15 development, validation, and clinical utility studies involving 5,000 scanned and diagnosed lesions.

Company description · DermaSensor official website